Skye Bioscience Inc
NASDAQ:SKYE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Suzhou Longjie Special Fiber Co Ltd
SSE:603332
|
CN |
|
L
|
Luxchem Corporation Bhd
KLSE:LUXCHEM
|
MY |
|
C
|
Celebrity Fashions Ltd
NSE:CELEBRITY
|
IN |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (13.3), the stock would be worth $1 440.87 (183 825% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | $0.78 |
0%
|
| Industry Average | 13.3 | $1 440.87 |
+183 825%
|
| Country Average | 14.4 | $1 555.28 |
+198 429%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Skye Bioscience Inc
NASDAQ:SKYE
|
26.1m USD | 0 | -0.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.1B USD | 14.3 | 85.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.7B USD | 13.9 | 23.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
168.6B USD | 12.2 | 19.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.5B USD | 21 | 28 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 12.8 | 17.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.8B EUR | 41.7 | 38.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.3B AUD | 10.9 | 32.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Skye Bioscience Inc
Glance View
Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2014-02-24. The Company’s products programs include THCVHS and CBDVHS. The firm's lead candidate, THCVHS, is a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). The company chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. Its molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases. CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical models.
